Results 21 to 30 of about 58,904 (306)

A brief overview of targeted radionuclide therapy trials in 2022

Frontiers in Nuclear Medicine, 2023
There is a growing use of radionuclide therapy for the medical care of oncology patients, where radioactive pharmaceuticals are used to target and treat various cancer types.
Aidan Healy, Elaine Ho, Phillip Kuo, Katherine Zukotynski   +3 more
doaj   +1 more source

Radioprotective Effect of Beta D-Glucan and Vitamin E on Gamma Irradiated Mouse [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: It is shown that beta-D-glucan is an immunologic system booster with radioprotectory effects. Radioprotectors are chemical components that can alleviate biological damage produced by ionizing radiation.
Faraj Tabeie, Seyed Mehdi Tabatabaei, Ali Mahmoud-Pashazadeh, Majid Assadi   +3 more
doaj   +1 more source

Theragnostic Radionuclide Pairs for Prostate Cancer Management: ⁶⁴Cu/⁶⁷Cu, Can Be a Budding Hot Duo

Biomedicines, 2022
Prostate cancer (PCa) is one of the preeminent causes of mortality in men worldwide. Theragnostic, a combination of therapy and diagnostic, using radionuclide pairs to diagnose and treat disease, has been shown to be a promising approach for combating ...
Anupriya Chhabra, Mathew L. Thakur
doaj   +1 more source

An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay

World Journal of Nuclear Medicine, 2020
Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein which is extremely overexpressed in prostate cancer epithelial cells. Recently, PSMA-targeted small molecule labeled with 68Ga and 99mTc allowed precise molecular imaging ...
Esmail Jafari, Hojjat Ahmadzadehfar, Habibollah Dadgar, Majid Assadi   +3 more
doaj   +1 more source

Management of biological waste of patients after radionuclide therapy

Радиационная гигиена, 2022
Radioactive waste management is a modern-day issue in terms of radiation safety due to the development of radionuclide therapy, the emergence of new radiopharmaceuticals, radionuclides, and treatment methods, which allow for radionuclide therapy in a day
L. A. Chipiga, A. V. Vodovatov, I. A. Zvonova, A. A. Stanzhevsky, A. V. Petryakova, E. E. Anokina, K. S. Velichkina, S. A. Ryzhov   +7 more
doaj   +1 more source

Radionuclides for Targeted Therapy: Physical Properties

Molecules, 2022
A search in PubMed revealed that 72 radionuclides have been considered for molecular or functional targeted radionuclide therapy. As radionuclide therapies increase in number and variations, it is important to understand the role of the radionuclide and ...
Caroline Stokke, Monika Kvassheim, Johan Blakkisrud   +2 more
doaj   +1 more source

First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer

Journal for ImmunoTherapy of Cancer, 2022
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is a validated treatment option for patients with advanced prostate cancer. Although PSMA expression is not limited to prostate tissue, little is known about its relevance to other ...
John Prior, Solange Peters, Krisztian Homicsko, Sarah Boughdad, Niklaus Schaefer, Antonia Digklia, Clarisse Dromain, Mounir Trimech, Ana Dolcan   +8 more
doaj   +1 more source

Hybrid Single-Photon Emission Computed Tomography/Computed Tomography Imaging Features of Tumoral Calcinosis in Technetium-99m Methylene Diphosphonate Bone Scintigraphy

World Journal of Nuclear Medicine, 2015
Tumoral calcinosis (TC) is an uncommon ectopic calcification syndrome. TC is a benign condition characterized by the presence of large calcific soft tissue deposits occurring predominantly in a periarticular location.
Koramadai Kamaleshwaran, Premkumar Asokumar, Anjali Malaikkal, Vyshakh Mohanan, Ajit Shinto   +4 more
doaj   +1 more source

Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer

Pharmaceutics, 2021
In recent years, radionuclide therapy (RT) and targeted radionuclide therapy (TRT) have gained great interest in cancer treatment. This is due to promising results obtained in both preclinical and clinical studies.
Tyrillshall S. T. Damiana, Simone U. Dalm   +1 more
doaj   +1 more source

Close contact restriction periods for patients who received iodine-131 therapy for differentiated thyroid cancer [PDF]

, 2022
Objective. Patients treated with radionuclide therapy may require restrictions on certain activities for a period of time following treatment to optimise protection of the public and ensure the legal dose limit is not exceeded. Software may be used to calculate necessary restriction periods for an individual based on longitudinal dose rate measurements
arxiv   +1 more source